Vanda Pharmaceuticals Inc
VNDA
Market Cap$281.71M
Close$
$10.84
129.7% upside
Current Fair Value
129.7% upsideUndervalued by 129.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $281.71 Million |
|---|---|
| Enterprise Value | $177.26 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.33 |
| Beta | 0.67 |
| Outstanding Shares | 58,527,775 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.32 |
|---|---|
| PEG | -1.03 |
| Price to Sales | 1.57 |
| Price to Book Ratio | 0.59 |
| Enterprise Value to Revenue | 0.88 |
| Enterprise Value to EBIT | -2.45 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.